Amgen's obesity drug, MariTide, demonstrated up to 20% weight loss in a Phase 2 trial, aligning with existing treatments like Zepbound and Wegovy. However, a higher dropout rate due to side effects raised concerns, leading to a decline in Amgen's stock. The company plans to initiate a Phase 3 study to further evaluate MariTide's efficacy and safety.
Eli Lilly"s experimental cholesterol pill, muvalaplin, has shown promising results in a mid-stage trial, significantly reducing levels of lipoprotein(a), a genetic risk factor for heart disease. The highest dose decreased Lp(a) by 70% compared to placebo, with a favorable safety profile. Analysts suggest the drug could become a blockbuster if it proves effective in preventing cardiovascular events in future trials.
Regeneron Pharmaceuticals' shares dropped nearly 10% as third-quarter sales of Eylea fell short of expectations, raising concerns about future sales amid competition. In contrast, Madrigal Pharmaceuticals reported strong sales of its MASH drug, Rezdiffra, totaling $62 million, significantly exceeding forecasts. UCB's Alzheimer’s drug trial showed promising secondary results despite missing its main goal, while AbbVie announced a partnership with EvolveImmune Therapeutics to develop cancer therapies.
Eli Lilly's third-quarter earnings fell short of Wall Street expectations, with revenue at $11.4 billion, missing forecasts of $12.1 billion. Sales of its obesity drugs, Mounjaro and Zepbound, reached $3.1 billion and $1.26 billion, respectively, but were lower than anticipated, leading to a significant drop in shares and a revised revenue guidance for the year. Despite these setbacks, company executives noted continued growth in underlying demand for their products.
A multibillion-dollar race is underway among pharmaceutical companies to develop superior obesity drugs, with key contenders like Eli Lilly's Zepbound and Novo Nordisk's Wegovy leading the market. Upcoming trial results for various drugs, including Amgen's maritide and Roche's CT-996, are highly anticipated and could reshape the competitive landscape. As companies explore innovative approaches, such as preserving muscle mass during weight loss, the future of obesity treatment remains dynamic and closely watched.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
